Cowen & Co Upgrades Incyte (INCY) to Outperform
More News related to INCY
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
- Novartis (NVS) Excites Incyte (INCY) with Licensing Deal
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Incyte (INCY) Enters Investigational Hermatology-Oncology Collaboration Agreement with Novartis (NVS)
Cowen & Co upgrades Incyte (Nasdaq: INCY) from Neutral to Outperform.
To see more analyst ratings on INCY Click Here.
Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.
Related Categories
UpgradesStocks Mentioned
-0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
